4-amino-4'-hydroxylaminodiphenylsulfone (HADS)

RN given refers to unlabeled cpd
Also Known As:
HADS; 4-amino-4'-hydroxylaminodiphenylsulfone, T-labeled cpd; 4-hydroxylamino-4'-aminophenyl sulfone; DDS-NOH; N-hydroxydapsone; dapsone hydroxylamine
Networked: 1183 relevant articles (27 outcomes, 149 trials/studies)

Relationship Network

Bio-Agent Context: Research Results


1. Grassi, Luigi: 11 articles (05/2013 - 08/2005)
2. Matsushima, Eisuke: 10 articles (06/2015 - 03/2004)
3. Martin, Colin R: 10 articles (02/2009 - 08/2003)
4. Dahl, Alv A: 10 articles (03/2008 - 02/2002)
5. Bruera, Eduardo: 9 articles (09/2015 - 02/2004)
6. Thompson, David R: 8 articles (01/2016 - 08/2003)
7. Hinz, Andreas: 8 articles (05/2015 - 01/2006)
8. Bunevicius, Adomas: 8 articles (02/2014 - 01/2007)
9. Bunevicius, Robertas: 8 articles (02/2014 - 01/2007)
10. Herrmann-Lingen, Christoph: 7 articles (06/2014 - 01/2002)

Related Diseases

1. Pain (Aches)
04/01/2013 - "During follow-up, patients improved all of their outcome measurements (physical and mental SF-36 scores, depression and anxiety HADS scores, pain VAS, EQ-5D Health State Index and VAS) and most patients remained on the same antidepressant at the same dose."
07/01/1998 - "There was no significant difference between the two groups at baseline nor in change of pain; reduction in use of analgesic medication; nor change in the HADS, MADRS, or SF36 scores at 12 weeks, but 72% of patients who completed the study improved, and this improvement almost exactly mirrored the improvement on the MADRS. "
03/01/2015 - "In contrast with diabetic patients having no foot problems, diabetic patients with foot problems had, on average, significantly greater symptoms of diabetes (Diabetes Symptom Checklist-2 score), greater depression symptoms (Hospital Anxiety and Depression Scale [HADS]-Depression score), worse health-related quality of life (Medical Outcome Study Short Form 36 [SF-36]: Physical Component Summary score and 6 of 8 subscales), greater pain (Short-Form McGill Pain Questionnaire), and greater suicidal behavior (Suicidal Behaviors Questionnaire-Revised). "
01/01/2010 - "Significant improvement, although with moderate effect sizes, were also observed in total FIQ scores, anxiety and depression scores (both HADS and BDI), and pain interference with daily activities. "
01/01/2009 - "Psychometric parameters (PDI, SF-12, QLIP, HADS) and pain intensity improved significantly during delta 9-THC treatment. "
2. Fatigue
3. Depressive Disorder (Melancholia)
4. Mental Disorders (Mental Disorder)
07/01/2005 - "The aim of this study is to determine if the HADS correctly identified patients with depression according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition [determined using the Primary Care Evaluation of Mental Disorders (PRIME-MD), a gold-standard diagnostic tool], as depressed and to determine which items on the HADS most strongly predicted the PRIME-MD major depression diagnosis among cardiac patients. "
01/01/2006 - "The study compared the discriminant validity of the Hospital Anxiety and Depression Scale (HADS) and the General Health Questionnaire (GHQ-12) to detect mental disorders in the most frequent chronic somatic diseases. "
10/01/2015 - "The average sensitivity/specificity was 85%/92% for the Structured Clinical Interview for DSM-IV-Axis-I Disorders (SCID-I), 95%/84% for the Mini International Neuropsychiatric Interview (MINI), < 70%/85% for the Primary Care Evaluation of Mental Disorders (PRIME-MD), 88%/78% for the Patient Health Questionnaire-9 (PHQ-9) with a cut-off score of 10, 69%/95% for PHQ-9 as a diagnostic algorithm and 70%/83% for the Hospital Anxiety and Depression Scale (HADS) with a cut-off score of 7. The confidence in the estimates for the other instruments was very low. "
08/30/2015 - "The presence of major (MD) and minor (md) depression was assessed with the Primary Care Evaluation of Mental Disorders (PRIME-MD), whereas its severity was evaluated with the Hospital Anxiety and Depression Scale (HADS). "
06/01/2015 - "Many instruments exist to assess mental disorders and anxiety, such as the hospital anxiety and depression scale (HADS). "
5. Neoplasms (Cancer)

Related Drugs and Biologics

1. ametantrone (HAQ)
2. Fluvoxamine (Luvox)
3. salicylhydroxamic acid (SHAM)
4. pregabalin (Lyrica)
5. propylene diquat (PDQ(+))
6. Radium
7. Alprazolam (Xanax)
8. BES
9. Dapsone
10. 4-amino-4'-hydroxylaminodiphenylsulfone (HADS)

Related Therapies and Procedures

1. Drug Therapy (Chemotherapy)
2. Therapeutics
3. Palliative Care (Palliative Medicine)
4. Horticultural Therapy
5. Defibrillators (Defibrillator)